We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: oncology
MedXY News
EnglishTag

oncology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer
GastroenterologyBiliary tract cancerimmunotherapy

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

By MedXY|Jan 11, 2026

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer
newsantibody-drug conjugatesbreast cancer

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY|Jan 9, 2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer
newsabemaciclibbreast cancer

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY|Jan 9, 2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC
newsmHSPConcology

Dual Blockade of AKT and AR Pathways: Capivasertib Plus Abiraterone Significantly Extends rPFS in PTEN-Deficient mHSPC

By MedXY|Jan 9, 2026

The CAPItello-281 trial shows that capivasertib plus abiraterone improves radiographic progression-free survival by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer, highlighting the importance of biomarker-driven t

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer
newsCarboplatinchemotherapy

Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer

By MedXY|Jan 8, 2026

The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors
newsbreast cancerhealth disparities

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

By MedXY|Jan 8, 2026

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for ad

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
Gastroenterologyimmunotherapyoncology

Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer

By MedXY|Jan 8, 2026

A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of

Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort
newsoncologypublic health

Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort

By MedXY|Jan 8, 2026

A large-scale prospective study of over 100,000 participants identifies significant associations between specific food preservatives, including sorbates, nitrites, and nitrates, and an increased risk of overall, breast, and prostate cancers

2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts
Internal Medicineoncology

2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts

By MedXY|Jan 7, 2026

A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients
CardiologybiomarkersCardiology

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients

By MedXY|Jan 5, 2026

A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.

Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study
Cardiologycardiovascular healthoncology

Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study

By MedXY|Jan 5, 2026

A longitudinal study of cancer survivors reveals that those maintaining ideal cardiovascular health, measured by the Life’s Simple 7 metric, significantly reduce their risk of all-cause and cancer-specific mortality through pathways i

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
Diabetes & Endocrinologydiabetesimmunotherapy

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

By MedXY|Dec 29, 2025

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu

Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities
Hematology-Oncologycancer-related fatigueoncology

Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities

By MedXY|Dec 28, 2025

A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases
Critical CareARDScritical care

Survival in Cancer Patients with ARDS: The YELENNA Study Challenges ECMO Utility in Severe Cases

By MedXY|Dec 27, 2025

The YELENNA prospective study reveals a 73.2% 90-day mortality rate for cancer patients with ARDS. Crucially, venovenous ECMO provided no survival benefit in severe cases, prompting a re-evaluation of current clinical guidelines and goals-o

Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer
newsoncologyprognostic markers

Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer

By MedXY|Dec 25, 2025

Recent studies on Low-Grade Endometrial Stromal Sarcoma (LG-ESS) identify cervical stromal involvement as a key prognostic marker and suggest that adjuvant radiotherapy offers no survival benefit, advocating for individualized, risk-adapted

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease
General SurgeryoncologyPapillary Thyroid Carcinoma

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

By MedXY|Dec 24, 2025

A comprehensive meta-analysis suggests that for intermediate-risk papillary thyroid carcinoma with unilateral lateral lymph node metastasis, lobectomy provides oncological outcomes comparable to total thyroidectomy, challenging the necessit

Occupation Matters: New Data Reveal Wide Disparities in US Cancer Mortality Among Working-Age Adults
newshealth equityoccupational health

Occupation Matters: New Data Reveal Wide Disparities in US Cancer Mortality Among Working-Age Adults

By MedXY|Dec 23, 2025

A comprehensive population study of 450,453 deaths identifies specific occupations, including fishing, mining, and funeral services, with disproportionately high cancer mortality, suggesting a complex interplay of workplace exposures and st

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
Hematology-Oncologycollaborative caredigital health

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

By MedXY|Dec 23, 2025

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surve

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
Hematology-Oncologyclinical trialsoncology

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care

By MedXY|Dec 22, 2025

A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
newsHNSCCimmunotherapy

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

By MedXY|Dec 23, 2025

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate

Prev
4 / 5
12345
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities